Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
暂无分享,去创建一个
F. Locatelli | B. Bonnotte | A. Vaglio | L. Mouthon | C. Montecucco | C. Kroegel | S. Monti | G. Emmi | X. Puéchal | C. Salvarani | D. Jayne | R. Sinico | L. Guillevin | G. Cassone | B. Terrier | B. Hellmich | T. Neumann | J. Kahn | M. Urban | B. Seeliger | N. Venhoff | J. Thiel | F. Schiavon | M. Samson | M. Groh | V. Teixeira | Juliane Mahrhold | M. Iudici | A. Troilo | T. Barba | M. Papo | Chiara Marvisi | C. Durel | C. Marvisi | J. Mahrhold
[1] William J. Astle,et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status , 2019, Nature Communications.
[2] M. Jadoul,et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.
[3] A. Vaglio,et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.
[4] H. Gouya,et al. Cardiac involvement in granulomatosis with polyangiitis: a magnetic resonance imaging study of 31 consecutive patients , 2017, Rheumatology.
[5] S. Yancey,et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.
[6] S. Heymans,et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. , 2015, International journal of cardiology.
[7] P. Merkel,et al. Cardiac Involvement in Granulomatosis with Polyangiitis , 2015, The Journal of Rheumatology.
[8] P. Ravaud,et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.
[9] D. D'cruz,et al. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). , 2014, Journal of autoimmunity.
[10] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.
[11] X. Bosch,et al. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. , 2009, Chest.
[12] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[13] H. Raspe,et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.
[14] L. Mouthon,et al. Antineutrophil Cytoplasmic Antibodies and the ChurgStrauss Syndrome , 2005, Annals of Internal Medicine.
[15] Laura Pavone,et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.
[16] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[17] R. Moots,et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.
[18] L. Mouthon,et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. , 2013, Arthritis and rheumatism.
[19] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[20] O. Lortholary,et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.